Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reno Debets

Showing results (121-130 of 134) with videos related to

Pageof 14
Sort By:
Thyroid : Official Journal of the American Thyroid Association|March 11, 2020
Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer PatientsEdwin A Basak, Jan W M van der Meer, Daan P Hurkmans, et al.
Journal for Immunotherapy of Cancer|May 29, 2020
Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancerDaan P Hurkmans, Edwin A Basak, Nina Schepers, et al.
Molecular & Cellular Proteomics : MCP|April 19, 2014
Ferritin heavy chain in triple negative breast cancer: a favorable prognostic marker that relates to a cluster of differentiation 8 positive (CD8+) effector T-cell responseNing Qing Liu, Tommaso De Marchi, Annemieke M Timmermans, et al.
Elife|September 20, 2022
Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapyAmit Gutwillig, Nadine Santana-Magal, Leen Farhat-Younis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cellsMaud Rijnders, Hayri E Balcioglu, Debbie G J Robbrecht, et al.
Journal for Immunotherapy of Cancer|June 5, 2021
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumorsDaan P Hurkmans, Sebastiaan D T Sassen, Karlijn de Joode, et al.
Journal for Immunotherapy of Cancer|July 21, 2019
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patientsDaan P Hurkmans, Edwin A Basak, Tanja van Dijk, et al.
Frontiers in Immunology|September 12, 2022
Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patientsFleur van der Sijde, Willem A Dik, Dana A M Mustafa, et al.
Cancer Discovery|August 22, 2024
TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast CancerDian Kortleve, Dora Hammerl, Mandy van Brakel, et al.
The Lancet Regional Health. Europe|May 13, 2026
A roadmap for supporting the development of advanced therapy medicinal products in a European frameworkJohan Van Eldere, Alessandro Aiuti, Silvia Martin Lluesma, et al.
Pageof 14

Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
Thyroid : Official Journal of the American Thyroid Association|March 11, 2020
Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer PatientsEdwin A Basak, Jan W M van der Meer, Daan P Hurkmans, et al.
Journal for Immunotherapy of Cancer|May 29, 2020
Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancerDaan P Hurkmans, Edwin A Basak, Nina Schepers, et al.
Molecular & Cellular Proteomics : MCP|April 19, 2014
Ferritin heavy chain in triple negative breast cancer: a favorable prognostic marker that relates to a cluster of differentiation 8 positive (CD8+) effector T-cell responseNing Qing Liu, Tommaso De Marchi, Annemieke M Timmermans, et al.
Elife|September 20, 2022
Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapyAmit Gutwillig, Nadine Santana-Magal, Leen Farhat-Younis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
Anti-PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cellsMaud Rijnders, Hayri E Balcioglu, Debbie G J Robbrecht, et al.
Journal for Immunotherapy of Cancer|June 5, 2021
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumorsDaan P Hurkmans, Sebastiaan D T Sassen, Karlijn de Joode, et al.
Journal for Immunotherapy of Cancer|July 21, 2019
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patientsDaan P Hurkmans, Edwin A Basak, Tanja van Dijk, et al.
Frontiers in Immunology|September 12, 2022
Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patientsFleur van der Sijde, Willem A Dik, Dana A M Mustafa, et al.
Cancer Discovery|August 22, 2024
TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast CancerDian Kortleve, Dora Hammerl, Mandy van Brakel, et al.
The Lancet Regional Health. Europe|May 13, 2026
A roadmap for supporting the development of advanced therapy medicinal products in a European frameworkJohan Van Eldere, Alessandro Aiuti, Silvia Martin Lluesma, et al.
Pageof 14